权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cardiomyocyte transplantation therapy for the congestive heart failure

心肌细胞移植治疗充血性心力衰竭

基本信息

批准号：
11671158
负责人：
KOMEDA Masashi
金额：
$ 2.3万
依托单位：
Kyoto University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1999
资助国家：
日本
起止时间：
1999 至 2000
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11671158/
关键词：
cell transplantation heart failure Angiogenesis bFGF 虚血性心筋症慢性心不全

项目摘要

This study was designed to estimate the potential benefit of cardiomyocyte transplantation as an alternative to cardiac transplantation. In each study we performed fetal cardiomyocyte transplantation to the rats with chronic myocardial infarction. <fetal cardiomyocyte transplantation > TX group had smaller end-systolic dimension and better fractional shortening than Control group. However, there were no differences in all parameters before and after transplantation in TX group. Fetal cardiomyocyte (fCM) transplantation only prevented but did not reverse cardiac remodeling in rats with chronic myocardial infarction. < fCM transplantation with bFGF> This study investigate the efficacy of prevascularization in ischemic regions prior to cell transplantation. FGF group received the gelatin hydrogel microspheres incorporating bFGF, and FGF-TX group received bFGF pretreatment sequentially followed by fCM transplantation. Neovascularization was found in the scar tissue one week after bFGF treatment. LV maximum time-varying elastance was higher in the FGF-TX group than in the TX and FGF groups. Histologically, more transplanted cells survived in the FGF-TX group than in the TX group. Prevascularization with bFGF-incorporated microspheres enhances the benefits of fCM transplantation. < fCM transplantation with left ventricular plasty> Fourty-seven rats with LV aneurysm underwent culture medium injection (CMI) (n=10 ; group I), fCM transplantation (CM-TX) (n=10 ; group II), LV repair with CMI (n=14 ; group III), or LV repair with fetal CM-TX (n=13 ; group IV), and were followed-up during the subsequent 4 weeks. In the late period, LV dimension in group IV was smaller than those in group III, although they initially showed similar decreases in both groups. At the final week, LVEmax in group IV was the highest among the groups. CM-TX exerted preventive effects against late LV dilation and dysfunction after LV repair surgery.

这项研究旨在评估心肌细胞移植作为心脏移植的替代方案的潜在益处。在每项研究中，我们对慢性心肌梗死大鼠进行了胚胎心肌细胞移植。胚胎心肌细胞移植组收缩末期内径小于对照组，缩短率好于对照组。而TX组移植前后各项指标均无明显差异。胚胎心肌细胞(FCM)移植只能预防慢性心肌梗死大鼠的心脏重构，但不能逆转其重构。本研究探讨细胞移植前在缺血区先行血运重建的效果。成纤维细胞生长因子组植入复合碱性成纤维细胞生长因子的明胶水凝胶微球，成纤维细胞生长因子-TX组依次接受碱性成纤维细胞生长因子预处理和FCM移植。碱性成纤维细胞生长因子治疗1周后，瘢痕组织中可见新生血管形成。成纤维细胞生长因子-TX组的LV最大时变弹性高于TX组和FGF组。组织学上，成纤维细胞生长因子-TX组的移植细胞存活率高于TX组。使用含碱性成纤维细胞生长因子的微球预血运增强了FCM移植的益处。47只大鼠接受了培养液注射(CMI)组(n=10)、FCM移植(CM-TX组)(n=10)、CMI修补术(n=14)和胎儿CM-TX修补术(n=13)，并在随后的4周内进行了随访。在晚期，IV组的LV内径小于III组，尽管两组最初表现出相似的减少。在最后一周，IV组的LVEmax在各组中最高。CM-TX对LV修复术后晚期LV扩张和功能障碍有预防作用。